国际麻醉学与复苏杂志   2023, Issue (4): 0-0
    
NR4A1及其翻译后修饰在炎症性相关肺实质 疾病中调控作用的研究进展
秦晓枫, 谷长平, 张芮芮, 杨丽, 闫秀青, 王月兰1()
1.山东第一医科大学第一附属医院
Research advances on the regulatory role of nuclear receptor subfamily 4 group A member 1 and its post‑translational modification in inflammatory‑associated pulmonary parenchymal diseases
 全文:
摘要：

核受体亚家族4A组成员1（nuclear receptor subfamily 4 group A member 1, NR4A1）是由多种应激源诱导的早期转录因子，参与细胞生理活动与病理进程，尤其是在炎症相关的肺部疾病中发挥关键的调节作用，且其活性表达受转录后修饰的调节。文章探讨了NR4A1在哮喘、急性肺损伤（acute lung injury, ALI）、肺动脉高压（pulmonary arterial hypertension, PAH）和慢性阻塞性肺疾病（chronic obstructive pulmonary diseases, COPD）中的调控作用，并对其小泛素相关修饰物（small ubiquitin‑like modifier, SUMO）修饰、磷酸化、乙酰化转录后修饰调节机制进行综述，为进一步明确NR4A1在肺实质性疾病中转录后修饰的调控机制及寻找临床肺实质相关疾病的防治靶点提供理论依据。
关键词： 核受体亚家族4A组成员1； 炎症； 肺实质疾病； 翻译后修饰
Abstract:

Nuclear receptor subfamily 4 group A member 1 (NR4A1) is an early transcription factor induced by various stressors involved in cell physiological activities and pathological processes, especially in inflammation‑related lung diseases. Its active expression is regulated by post‑transcriptional modification. This article discusses the regulatory role of NR4A1 in asthma, acute lung injury (ALI), pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and so on. Besides, it reviews the regulatory mechanisms of NR4A1's small ubiquitin‑like modifier (SUMO) modify, phosphorylation, acetylation, and post‑transcriptional modification in these pulmonary parenchymal diseases. This review further clarifies the regulatory mechanism of post‑transcriptional modification of NR4A1 in pulmonary parenchymal diseases and provides a theoretical basis for finding clinical targets for preventing and treating pulmonary parenchymal disorders.
Key words: Nuclear receptor subfamily 4 group A member 1; Inflammation; Pulmonary parenchymal diseases; Post‑transcriptional modification